CARs have provided a powerful approach to targeting T cells and with the efficacy and durability of this cell therapy touting claims of providing a “cure” to cancer. We must now look beyond the successful CD19 therapies and start thinking about solid tumours and ways in which we can see similar efficacies and durability’s for these other cancers.
On a mission to understand what the future holds for CAR-NKs, we briefly spoke to Katy Rezvani, Chief, Section of Cellular Therapy at department of Stem Cell Transplantation & Cellular Therapy.
To date, the clinical results in solid tumour trials have been lack lustre. There are several aspects of development that need to be improved in the next generation of CAR-T and TCR approaches to ensure success.
The following report focuses on the key aspects of ensuring successful development of CAR-T therapies in liquid tumours to solid tumours in order to affect disease in broader indications and save larger numbers of patients’ lives.
On a mission to find out what the future holds for the CAR-TCR space, we sat down with: Hans Bishop, CEO, Juno Therapeutics; André Choulika, CEO, Cellectis; Laurence Cooper, CEO, ZIOPHARM and David Chang, CMO, Kite Pharma to talk shop.
The industry results provide some great insights into manufacturing challenges, key design factors for the next generation of CAR-TCR therapies and pricing models for these therapies.
Stephanie Farnia, Director, Payer Policy, Be the Match Biotherapiesdiscusses payer coverage, coding and reimbursement challenges
Kevin Friedman, Director, bluebird bio is discussing the key considerations of cost, scalability and bioactivity of CAR-T cell manufacturing
Sadik Kassim, former Associate Director, Cell and Gene Therapies Unit at Novartis now VP at Mustang Bio discussed the Characterization of CAR-T Therapies and advancing towards precision.
Kimberly Freeman, VP Commercial Strategy, Adaptimmune
Donna Rill, Vice President of Manufacturing, Cell Medica